Our products

Broad range portfolio

Alvogen’s US Generic portfolio focuses on niche generics, transdermal patches, narcotics, controlled release, and first to file and first to market products. There are currently over 75 pipeline ANDA filings for the U.S. market. 

We offer high quality, affordable generic medications that help reduce healthcare costs around the world. Our targets are complex products and we provide strong supply levels.

U.S. manufacturing facility

Alvogen’s future is built on the strong foundation of Alvogen’s Norwich, NY manufacturing site – a leading full-service pharmaceutical manufacturer with multi-dosage form capabilities for Rx and OTC products in the U.S., E.U. and international markets. Alvogen’s Norwich, NY manufacturing site has long set the standard for service, quality and innovation from introducing the first antiseptic surgical dressing to being the first to mass produce Pepto-Bismol.  This site currently maintaining a 20-year compliance record without a single FDA-483 citation.

Alvogen's Norwich, NY manufacturing site's development and manufacturing capabilities include:

  • 385,000 square-foot facility
  • 3.5b tablets with facility, 1.5 billion with current equipment
  • Tablets, coated tablets, hard capsules and liquid filled capsules, liquid.
  • Pilot scale manufacturing suites
  • Commercial scale manufacturing suites
  • 20-year compliance record with no FDA-483 citations

Alvogen R&D Center

Cutting-edge research that yields customer-centric generics.

Headquartered in Pine Brook, New Jersey, our innovation research and development facility develops first-to-file and complex generic pharmaceutical products, including controlled release pharmaceuticals, that will be manufactured in our state-of-the-art U.S. manufacturing facility.

Staffed with multiple teams of seasoned professionals in both formulation and analytical chemistry, all with proven track records in filing and bringing to market first-to-file ANDAs, our R&D center strengthens our in-house development capabilities. These expanded internal capabilities form an important cornerstone of our targeted development strategy – a strategy designed to bring even more high-quality, low-cost generics to your shelves.


Our goal is to ensure that the benefits and risks of a medication are continuously monitored and well-understood by regulators, healthcare providers and patients. Alvogen maintains a pharmacovigilance system, collecting information over the lifecycle of each product.